Sustainability & Climate

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

Supremex reports strong Q4 growth driven by its packaging division, erasing nearly all debt and positioning itself for an aggressive future beyond envelopes.

At a major scientific conference, Seer Inc.'s Proteograph platform is taking center stage, promising deeper insights into Alzheimer's and heart disease.

With a pivotal data release on the horizon, Passage Bio heads to two major conferences. Can its dementia gene therapy program win over Wall Street?

As Signet prepares its Q4 earnings, all eyes are on whether its brand power can overcome cautious consumer spending and set the tone for the luxury market.

With a new $50M facility from CIBC, Montreal-based AlayaCare is poised to accelerate its M&A strategy and advance its mission to digitize home care.

A strategic acquisition makes Made in America Gold the largest junior landholder in Nevada, setting the stage for a new gold rush in a proven, yet untapped, region.

Leo's strategic investment unites two engineering firms, adding nearly 300 experts to challenge national facilities management leaders.

With BRINSUPRI revenues set to hit $1B, Insmed is pouring cash into a high-stakes pipeline. Can it outrun its massive burn rate to deliver the next breakthrough?

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

Emirates Health Services launches 'Amal,' the UAE's first AI physician assistant, aiming to enhance patient care and streamline clinical workflows.

Early data reveals a novel immunotherapy, STC-1010, may activate the immune system against a common, treatment-resistant form of colorectal cancer.

vivo's new V70 challenges the premium market with a powerful ZEISS telephoto lens, a massive battery, robust IP69 rating, and a long-term software promise.

As argenx prepares its full-year 2025 update, investors are watching if the VYVGART sales boom can fund a pipeline aimed at dominating autoimmune care.

The precision tech firm posted record Q1 sales of $669M and a 15% jump in adjusted EPS, driven by a 21% surge in its semiconductor-focused segment.

With impressive preliminary sales and key pipeline updates, Mirum Pharmaceuticals' upcoming earnings call will focus on its strategy for sustained growth in 2026.

TPL shatters 2025 financial records despite price headwinds, fueled by strategic acquisitions and a major $50 million investment in data infrastructure.

A landmark deal with Abu Dhabi's SSMC will make the UAE a regional hub for Nyxoah's innovative Genio implant, targeting a major health issue.

The global underwriter posts stellar earnings, announces strategic acquisitions in the travel sector, and launches a $100M share buyback.

Caesarstone will release its 2025 results without a conference call, a move raising investor questions amid a year of losses and strategic overhaul.